Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$784.21M+142.15%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott E. Russell
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 9,626
- Beta
- 0.04
- Country
- IL
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.23
Financials
Revenue
$784.21M+142.1%Net Income
$94.29M+261.3%EBITDA
$183.72M+184.5%Free Cash Flow
$89.17M+267.1%EPS (diluted)
$1.59+269.8%Shares Outstanding (diluted)
59.31M-3.3%Operating Expenses
$364.97MCash & Debt
$350.94MReturn of Capital
$70.76MRevenue by Segment (annual)
$2.95BDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.95B | $612.10M | $9.82 |
| 2024 | $2.74B | $442.59M | $6.97 |
| 2023 | $2.38B | $338.30M | $5.32 |
| 2022 | $2.18B | $265.94M | $4.17 |
| 2021 | $1.92B | $199.22M | $3.15 |
| 2020 | $1.65B | $196.35M | $3.14 |
| 2019 | $1.57B | $185.90M | $2.99 |
| 2018 | $1.44B | $159.34M | $2.60 |
| 2017 | $1.33B | $143.29M | $2.37 |
| 2016 | $1.02B | $116.92M | $1.96 |
| 2015 | $926.87M | $258.83M | $4.35 |
| 2014 | $1.01B | $103.08M | $1.74 |
| 2013 | $949.28M | $55.27M | $0.92 |
| 2012 | $879.01M | $67.89M | $1.11 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NICE's reported EPS growth of 18.3% a year over 13 years.
- EPS in 5 years
- $22.75
- Implied price
- $273.03
- Return from $85.22
- 26.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $135.74 — today's price is already 37.2% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| 8.3% | 6.6% | 11.4% | 15.6% | 19.2% | 22.4% |
| 13.3% | 11.5% | 16.6% | 20.9% | 24.7% | 28.0% |
| 18.3% | 16.4% | 21.7% | 26.2% | 30.2% | 33.7% |
| 23.3% | 21.3% | 26.8% | 31.6% | 35.7% | 39.3% |
| 28.3% | 26.2% | 32.0% | 36.9% | 41.2% | 45.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (22)
- Newszacks.com·2d ago·Neutral
Nice (NICE) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Nice (NICE). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newsseekingalpha.com·15d ago·Positive
NICE Ltd. Is Growing While The Market Stays Skeptical NICE Ltd. maintains a Strong Buy rating, supported by resilient revenue growth, robust AI ARR up 46%, and an expanding CXone backlog. Despite margin compression and integration costs, NICE reiterates 2026 revenue guidance and raises the non-GAAP EPS outlook to $11.12–$11.32. Valuation remains deeply discounted—forward EV/EBITDA and P/E multiples are over 50% below sector medians, offering significant upside if margins recover.
View source ↗ - Newsmarketbeat.com·18d ago·Negative
NiCE Q3 Earnings Call Highlights NiCE NASDAQ: NICE reported third-quarter revenue and adjusted earnings above the high end of its guidance, while management said it is taking steps to improve cloud growth and streamline operations through a workforce reduction of about 5%.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome -- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, …
View source ↗ - Newsbusinesswire.com·18d ago·Negative
NiCE Exceeds Revenue and EPS Guidance Ranges, Reporting 8% Year-Over-Year Revenue Growth in Third Quarter 2026 HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (NASDAQ: NICE) today announced results for the third quarter ended September 30, 2026, as compared to the corresponding period of the previous year. Third Quarter 2026 Financial Highlights GAAP Non-GAAP Total revenue was $790.7 million and increased 8.0%* Total revenue was $790.7 million and increased 8.0%* Cloud revenue was $622.7 million and increa…
View source ↗ - Newszacks.com·23d ago·Neutral
Ahead of Nice (NICE) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Nice (NICE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newszacks.com·27d ago·Positive
Nice (NICE) Beats Stock Market Upswing: What Investors Need to Know Nice (NICE) concluded the recent trading session at $122.41, signifying a +1.02% move from its prior day's close.
View source ↗ - Newszacks.com·32d ago·Neutral
Wall Street Analysts See Nice (NICE) as a Buy: Should You Invest? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·32d ago·Neutral
Investors Heavily Search Nice (NICE): Here is What You Need to Know Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·34d ago·Positive
Nice (NICE) Beats Stock Market Upswing: What Investors Need to Know Nice (NICE) closed at $113.84 in the latest trading session, marking a +1.49% move from the prior day.
View source ↗ - Newszacks.com·41d ago·Negative
Nice (NICE) Declines More Than Market: Some Information for Investors Nice (NICE) reached $115.02 at the closing of the latest trading day, reflecting a -2.1% change compared to its last close.
View source ↗ - Newsfool.com·43d ago·Neutral
NICE Stock Analysis: Buy or Sell? Investors are curious if this is a value stock or a value trap.
View source ↗ - Newszacks.com·44d ago·Neutral
Here is What to Know Beyond Why Nice (NICE) is a Trending Stock Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
View source ↗ - Newszacks.com·48d ago·Positive
Should You Invest in Nice (NICE) Based on Bullish Wall Street Views? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newsglobenewswire.com·48d ago·Negative
NiCE Names Carahsoft Distributor of the Year for 2025 Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions
View source ↗ - Newszacks.com·51d ago·Negative
Nice (NICE) Stock Declines While Market Improves: Some Information for Investors In the closing of the recent trading day, Nice (NICE) stood at $113.81, denoting a -2.3% move from the preceding trading day.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
NICE: Growth Numbers Look Ugly, But The Setup Is Improving NICE Ltd. remains a Buy, with AI-driven growth and a low valuation underpinning the investment thesis. AI and Self-Service ARR surged 52% year-over-year, now 15% of cloud revenue, signaling robust demand and platform relevance. Margin compression persists as NICE invests in AI and expansion, but strong cash flow and buybacks provide downside protection.
View source ↗ - Newszacks.com·55d ago·Neutral
Nice (NICE) is Attracting Investor Attention: Here is What You Should Know Nice (NICE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·59d ago·Neutral
Nice (NICE) Dips More Than Broader Market: What You Should Know In the most recent trading session, Nice (NICE) closed at $113.86, indicating a -3.34% shift from the previous trading day.
View source ↗ - Newszacks.com·69d ago·Neutral
Nice (NICE) Is a Trending Stock: Facts to Know Before Betting on It Nice (NICE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsseekingalpha.com·94d ago·Positive
NICE Has More Upside Than The Market Sees NICE remains deeply undervalued, with robust cloud and AI revenue growth and a resilient recurring earnings base. Q2 results exceeded guidance: revenue up 7.6%, cloud revenue up 12.6%, and AI ARR up 52%, supporting a Strong Buy rating. Management raised 2026 EPS guidance to $11.06–$11.26, reaffirmed 8% revenue growth, and expects operating margins at the high end of 25–26%.
View source ↗ - Newsseekingalpha.com·97d ago·Neutral
NICE Posts Another Nice Earnings Beat, As AI-Driven Software Sees Enterprise Demand NICE Ltd earns a buy rating, driven by AI-powered growth, global scale, and low leverage despite near-term earnings headwinds. NICE's CXone platform benefits from rising enterprise demand for AI-driven customer engagement, with proven global penetration and Fortune 100 clientele. Revenue diversification and steady 5-year growth differentiate NICE from smaller tech peers, though North American exposure remains a …
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $3.05 per share
Typical surprise +1.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$2.84 vs $2.78beat
- Wed, Aug 5$2.70 vs $2.63beat
- Wed, May 6$2.64 vs $2.52beat
- Thu, Feb 19$3.24 vs $3.21beat
- Thu, Nov 13$3.18 vs $3.17beat
- Thu, Aug 14$3.01 vs $2.99beat
Estimates and results for NICE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NICE officers and directors.
- Bought
- —
- Sold
- $50k
0 trades
1 trade
- Dayan Udi Yehudasold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh Gottheimerhouse · NJ05 · disclosed Aug 11, 2026 (22d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 18, 2025 (32d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (28d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Feb 24, 2023 (42d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2020 (27d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 19, 2020 (27d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 19, 2020 (29d later)Sell$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (21d later)Sell$1,001 - $15,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
